 Highlighting the intense competition and sometimes unpredictability of the biopharma space, sector giant Gilead Sciences NASDAQ: GILD stock is down roughly 2 today. While the companys experimental treatment for metastatic non-small cell lung cancer developed alongside Arcus Biosciences NYSE: RCUS produced some positive results, it failed to compete against a rival therapeutic. 